PRESS RELEASE – Cognitive Research Corporation Names Alison Taber Senior Vice President, Data Management
Cognitive Research Corporation names Alison Taber SVP Data Management
Menu
Cognitive Research Corporation (CRC) is a privately-held, full-service contract research organization that specializes in Central Nervous System (CNS) product development for pharmaceutical, nutraceutical, biotechnology and medical device companies. With offices in Florida and an integrated network of experienced research facilities, CRC is well-positioned to conduct clinical studies at any stage, Phase I-IV.
CRC provides comprehensive CRO services with a focus on maintaining a personal connection with our clients.
CRC’s customized driving simulator (the CRCDS) is used to evaluate the effects of age, trauma, neurologic disease, alcohol and fatigue on driving performance. The CRCDS is also designed to study the effects of a wide variety of drugs on driving abilities in both normal and patient populations.
Cognitive Research Corporation names Alison Taber SVP Data Management
CRC partnered with BioXcel Therapeutics on FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. This program was from first-in-human trials through NDA approval. With this approval, BioXcel becomes the first and only FDA-approved orally dissolving sublingual film for mild, moderate, or severe agitation in patients with schizophrenia or bipolar disorder. Tom Hochadel, President of CRC, commented, “It is very rare for a clinical service company to work with a sponsor from first-in-human to NDA approval of a new drug. CRC and BioXcel have been collaborating on this program since 2018 and have worked cohesively and rapidly to move this innovative new therapy to approval. CRC is proud of their ability to deliver scientific and clinical development expertise to this program.”
Cognitive Research Corporation (CRC), a leading neuroscience clinical services company, announced that C. Gordon “Chip” Gillooly has been named Chief Executive Officer. Mr. Gillooly succeeds Dr. Tom Hochadel, Co-Founder, who will now serve as President and will continue to play an integral role in the company’s growth and delivery of exceptional CRO services to our clients. Dr. Gary Kay, Co-Founder and Head of Psychometric Assessments, will remain Chief Science Officer. CRC has been supporting clinical development for CNS-focused small to mid-size pharma, biotech, and medical device companies for over 16 years. The company has experienced explosive growth over the past five years as the CNS market has accelerated.
Sign up to receive email newsletters, notifications of events, and other information from Cognitive Research Corporation
CRC is well-positioned to conduct clinical studies at any stage, Phase I-IV.